Fourth Quarter and Full-Year 2024 Financial Results WHEN: 1:30-2:30 p.m. (PST) NUMBERS: 1-888-673-9780 ? for callers in the U.S. 1-312-470-0178 ? for ...

Full year 2024 net income of $320.4 million set a new Company record, increasing 15% compared to 2023.Full year 2024 diluted earnings per common share of $6.30 reached the highest level in Company ...

Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and full year 2024 financial results will be released ...

Novartis AG NVS, a Swiss pharma giant, is scheduled to report fourth-quarter 2024 and full-year results on Jan. 31, 2025. The ...

Exelixis (EXEL) has recently gained traction in the rapidly growing oncology market with its promising pipeline and strong ...

Exelixis Inc (EXEL) stock saw a modest uptick, ending the day at $32.73 which represents a slight increase of $0.35 or 1.08% from the prior close of $32.38. The stock opened at $32.92 and touched a ...

Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Stephens reiterated their equal weight rating on shares of Exelixis (NASDAQ:EXEL – Free Report) in a research report report ...